How to buy Castle Biosciences stock

Castle Biosciences, Inc is a diagnostics & research business based in the US. Castle Biosciences shares (CSTL) are listed on the NASDAQ and all prices are listed in US Dollars. Castle Biosciences employs 199 staff and has a trailing 12-month revenue of around 0.00.

Castle Biosciences share price

Use our graph to track the performance of CSTL stocks over time.

Castle Biosciences shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$26.13 - $107.69
50-day moving average	$66.46
200-day moving average	$65.56
Wall St. target price	$85.80
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-3.14

Buy Castle Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Castle Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Castle Biosciences, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Castle Biosciences under- or over-valued?

Valuing Castle Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Castle Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Castle Biosciences's EBITDA

Castle Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.9 million.

The EBITDA is a measure of a Castle Biosciences's overall financial performance and is widely used to measure a its profitability.

Castle Biosciences financials

Revenue TTM	$62.6 million
Gross profit TTM	$53 million
Return on assets TTM	-1.88%
Return on equity TTM	-4.11%
Profit margin	-16.42%
Book value	$4.82
Market capitalisation	$1.7 billion

TTM: trailing 12 months

Shorting Castle Biosciences shares

There are currently 2.2 million Castle Biosciences shares held short by investors – that's known as Castle Biosciences's "short interest". This figure is 7.1% down from 2.4 million last month.

There are a few different ways that this level of interest in shorting Castle Biosciences shares can be evaluated.

Castle Biosciences's "short interest ratio" (SIR)

Castle Biosciences's "short interest ratio" (SIR) is the quantity of Castle Biosciences shares currently shorted divided by the average quantity of Castle Biosciences shares traded daily (recently around 322318.32844575). Castle Biosciences's SIR currently stands at 6.82. In other words for every 100,000 Castle Biosciences shares traded daily on the market, roughly 6820 shares are currently held short.

However Castle Biosciences's short interest can also be evaluated against the total number of Castle Biosciences shares, or, against the total number of tradable Castle Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Castle Biosciences's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Castle Biosciences shares in existence, roughly 90 shares are currently held short) or 0.1314% of the tradable shares (for every 100,000 tradable Castle Biosciences shares, roughly 131 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Castle Biosciences.

Find out more about how you can short Castle Biosciences stock.

Castle Biosciences share dividends

We're not expecting Castle Biosciences to pay a dividend over the next 12 months.

Castle Biosciences overview

Castle Biosciences, Inc. , a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas. .

Frequently asked questions

• What percentage of Castle Biosciences is owned by insiders or institutions?

  Currently 10.746% of Castle Biosciences shares are held by insiders and 88.015% by institutions.

• How many people work for Castle Biosciences?

  Latest data suggests 199 work at Castle Biosciences.

• When does the fiscal year end for Castle Biosciences?

  Castle Biosciences's fiscal year ends in December.

• Where is Castle Biosciences based?

  Castle Biosciences's address is: 820 South Friendswood Drive, Friendswood, TX, United States, 77546

• What is Castle Biosciences's ISIN number?

  Castle Biosciences's international securities identification number is: US14843C1053

• What is Castle Biosciences's CUSIP number?

  Castle Biosciences's Committee on Uniform Securities Identification Procedures number is: 147905103